Nick DeMartinis, MD
Nick received his bachelor’s degree in chemical engineering at Georgia Tech, his M.D. from the Medical College of Georgia, and did his Psychiatry Residency and a Postdoctoral Fellowship in clinical psychopharmacology at the Hospital of the University of Pennsylvania Department of Psychiatry. He joined the faculty at Penn in 1995 in the Mood and Anxiety disorders Section working with Karl Rickels M.D., and began managing the clinical research operations of the primary site and a satellite research clinic in 1997. Nick joined the Department of Psychiatry at the University of Connecticut School of Medicine in 2000 to develop and manage a clinical research unit, and continued his clinical research activities until joining Pfizer; he currently maintains a faculty position there and continues educational activities in the psychiatry residency and medical school. Nick came to Pfizer in 2006 after 13 years as a clinical investigator, during which he conducted 24 industry clinical trials as principal investigator and participated in numerous industry trials as a sub-investigator across psychiatric indications including major depression, bipolar mania and depression, GAD, social anxiety disorder, PTSD, schizophrenia, attention deficit disorder, insomnia, alcohol dependence, benzodiazepine dependence, among others.
Nick is currently a Senior Director, in the Psychiatry Clinical group of the Neuroscience Research Unit in Cambridge, MA. At Pfizer he has participated in the design and conduct of Phase 1 single-dose, multiple-dose, biomarker, and POC studies for compounds in development for schizophrenia monotherapy, adjunctive treatment of negative symptoms in schizophrenia, and adjunctive treatment of cognitive impairment associated with schizophrenia. He is also the Clinical Lead for an exploratory human biology study in the treatment of age-related sensorineural hearing loss. Nick is an active member of psychiatry disease area strategy teams coordinating activities between the Primary Care Business Unit and the Neuroscience Research Unit, a member of the team managing the strategy and assessment of external drug development opportunities, and a Pfizer representative in a number of pre-competitive consortia including the IMI NEWMEDS collaboration, regulatory workgroups in the ISCTM, and efforts to develop standardizedstandardised clinical trial rater training and certification.